Vaxart Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Vaxart Inc Company

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Vaxart Inc Info



Ticker SymbolVXRT

Company nameVaxart Inc

IPO dateMar 17, 1980

CEOMr. Steven (Steve) Lo

Number of employees105

Security typeOrdinary Share

Fiscal year-endMar 17

Address170 Harbor Way, Suite 300

CitySOUTH SAN FRANCISCO

Stock exchangeUS 'Other OTC' and Grey Market

CountryUnited States of America

Postal code94080

Phone16505503500

Websitehttps://vaxart.com/

Ticker SymbolVXRT

IPO dateMar 17, 1980

CEOMr. Steven (Steve) Lo

Company Executives of Vaxart Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Edward B. Berg

Senior Vice President, General Counsel

435.74K

+1053.17%

Mr. Jeroen Grasman

Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer

350.00K

--

Mr. Steven (Steve) Lo

President, Chief Executive Officer, Director

140.14K

+249.14%

Dr. Elaine J. Heron, Ph.D.

Independent Director

40.57K

-21.46%

Dr. Sean N. Tucker, Ph.D.

Senior Vice President, Chief Scientific Officer

--

Mr. W. Mark Watson

Lead Independent Director

--

Dr. James F. Cummings, M.D.

Chief Medical Officer

--

Mr. Kevin P. Finney

Independent Director

--

Mr. Matt Stein

IR Contact Officer

--

Ms. Laurie Hastings

Senior Vice President of Human Resources

--

Name

Name/Position

Position

Shareholding

Change

Mr. Edward B. Berg

Senior Vice President, General Counsel

435.74K

+1053.17%

Mr. Jeroen Grasman

Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer

350.00K

--

Mr. Steven (Steve) Lo

President, Chief Executive Officer, Director

140.14K

+249.14%

Dr. Elaine J. Heron, Ph.D.

Independent Director

40.57K

-21.46%

Dr. Sean N. Tucker, Ph.D.

Senior Vice President, Chief Scientific Officer

--

Mr. W. Mark Watson

Lead Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Aug 23

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

4.55%

Geode Capital Management, L.L.C.

1.02%

BlackRock Institutional Trust Company, N.A.

0.77%

Marshall Wace LLP

0.77%

State Street Investment Management (US)

0.37%

Other

92.52%

Shareholders

Proportion

The Vanguard Group, Inc.

4.55%

Geode Capital Management, L.L.C.

1.02%

BlackRock Institutional Trust Company, N.A.

0.77%

Marshall Wace LLP

0.77%

State Street Investment Management (US)

0.37%

Other

92.52%

Shareholder Types

Shareholders

Proportion

Investment Advisor

6.48%

Investment Advisor/Hedge Fund

2.67%

Individual Investor

1.44%

Hedge Fund

0.42%

Research Firm

0.20%

Bank and Trust

0.04%

Family Office

0.03%

Venture Capital

0.01%

Other

88.70%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

199

22.43M

9.80%

-28.43M

2025Q2

223

30.23M

13.21%

-34.48M

2025Q1

260

32.73M

14.34%

-33.64M

2024Q4

273

38.15M

16.82%

-29.38M

2024Q3

304

39.77M

17.54%

-31.47M

2024Q2

307

43.16M

19.03%

-9.14M

2024Q1

311

42.29M

24.34%

-1.37M

2023Q4

307

17.70M

11.60%

-12.17M

2023Q3

319

19.94M

13.09%

-20.38M

2023Q2

329

30.49M

20.10%

-12.31M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

10.42M

4.55%

+48.72K

+0.47%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.33M

1.02%

-333.75K

-12.55%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.77M

0.77%

-9.88K

-0.55%

Jun 30, 2025

Marshall Wace LLP

1.76M

0.77%

+1.76M

--

Jun 30, 2025

State Street Investment Management (US)

851.12K

0.37%

+60.87K

+7.70%

Jun 30, 2025

UBS Financial Services, Inc.

748.02K

0.33%

+225.81K

+43.24%

Jun 30, 2025

Finney Michael J

686.84K

0.3%

-16.00K

-2.28%

Jul 29, 2025

Lee (Phillip E.)

631.62K

0.28%

+397.95K

+170.31%

Mar 24, 2025

Renaissance Technologies LLC

597.44K

0.26%

+597.44K

--

Jun 30, 2025

Squarepoint Capital LLP

446.85K

0.2%

-357.62K

-44.45%

Jun 30, 2025

Related ETFs



Updated: 3 hours ago

Name

Proportion

Invesco RAFI US 1500 Small-Mid ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0%

Fidelity Nasdaq Composite Index ETF

Proportion0%

Invesco NASDAQ Future Gen 200 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data